Материалы доступны только для специалистов сферы здравоохранения.
Чтобы посмотреть материал полностью
Авторизуйтесь
или зарегистрируйтесь.
Сочетание артериальной гипертензии и атеросклероза
Сочетание артериальной гипертензии и атеросклероза
Сочетание артериальной гипертензии и атеросклероза. Участковый терапевт. 2017; 5: 5-6.
Материалы доступны только для специалистов сферы здравоохранения.
Чтобы посмотреть материал полностью
Авторизуйтесь
или зарегистрируйтесь.
Аннотация
В настоящее время артериальная гипертензия (АГ) и атеросклероз являются наиболее важными факторами риска развития сердечно-сосудистых заболеваний (ССЗ), что требует адекватного терапевтического вмешательства для первичной и вторичной профилактики [1].
Полный текст
Список литературы
1. Павлова О.С. Современные возможности эффективной сердечно-сосудистой профилактики у пациентов с артериальной гипертензией и дислипидемией. Мед. новости. 2012; 1: 62–68.
2. Артериальная гипертония, нарушения липидного обмена и атеросклероз. В.В.Кухарчук. В кн.: Руководство по артериальной гипертонии. Под ред. Е.И.Чазова, И.Е.Чазовой. М.: Медиа Медика, 2005; 289–99.
3. Klahr S, Morrissey JJ. The role of vasoactive compounds, growth factors and cytokines in the progression of renal disease. Kidney Int 2000; 57 (Suppl. 75): 7–14.
4. Wolf G. The Renin-Angiotensin System and Progression of Renal Disease. Jn: Contributions to Nephrology. Editor G. Wolf. 2001.
5. Delcayre C, Swynghedauw B. Molecular mechanisms of myocardial remodelling. The role of aldosterone. J Mol Cell Cardiology 2002; 34: 1577–84.
6. Ross R. Atherosclerosis an inflammatory disease. N Engl J Med 1999; 340:115–26.
7. O’Donnell VB. Free radicals and lipid signaling in endothelial cells. Antiox Redox Signal 2003; 5: 195–203.
8. Wolfrum S, Jensen KS, Liao JK. Endothelium-dependent effects of statins. Arterioscler Thromb Vasc Biol. 2003; 23: 729–36.
9. Kaplan M, Aviram M. Oxidized low density lipoprotein: atherogenic and proinflammatory characteristics during macrophage foam cell formation. An inhibitory role for nutritional antioxidants and serum paraoxonase. ClinChem Lab Med 1999; 37: 777–87.
10. Campese VM, Bianchi S, Bigazzi R. Association between hyperlipidemia andmicroalbuminuria in essential hypertension. Kidney Int 1999; 56 (Suppl. 71): S10–3.
11. Stary HC, Blankenhorn DH, Chandler AB et al. A definition of the intima of human arteries and of its atherosclerosis-prone regions: a report from the Committee on Vascular Lesions of the Council on Arteriosclerosis, American Heart Association. Special report. Circulation 1992; 85: 391–405. [Medline]
12. Dartsch PC, Bauriedel G, Schinko I et al. Cell constitution and characteristics of human atherosclerotic plaques selectively removed by percutaneous atherectomy. Atherosclerosis 1989; 80: 149–57.
13. Blacker DJ, Flemming KD, Link MJ, Brown RD Jr. The preoperative cerebrovascular consultation: common cerebrovascular questions before general or cardiac surgery. Mayo Clin Proc 2004; 79: 223–9.
14. Kalinowski L, Dobrucki LW, Brovkovych V, Malinski T. Increased nitric oxide bioavailability in endothelial cells contributes to the pleiotropic effect of cerivastatin. Circulation 2002; 105: 933–8
15. Kalinowski L, Dobrucki LW, Malinski T. Cerivastatin potentiates nitric oxide release and eNOS expression through inhibition of isoprenoids synthesis. J Physiol Pharmacol 2002; 53: 585–95.
16. Morikawa S, Takabe W, Mataki C et al. The effect of statins on mRNA levels of genes related to inflammation, coagulation and vascular constriction in HUVEC. Human umbilical vein endothelial cells. J Atheroscler Thromb 2002; 9: 177–83.
17. Laufs U, Gertz K, Dirnagl U et al. Rosuvastatin, a new-CoA reductase inhibitor, upregulates endothelial nitric oxide synthase and protects from ischaemic stroke in mice. Brain Res 2002; 942: 23–30.
18. Dahlof B, Poulter N, Sever PS. Do statins lower blood pressure? Evidence from the Anglo-Scandinavian Cardiac Outcomes Trial – Lipid-Lowering Arm (ASCOT-LLA) (abstract). Circulation 2004; 110: 402.
19. John S, Schneider MP, Delles C et al. Lipid-independent effects of statins on endothelial function and bioavailability of nitric oxide in hypercholesterolemic patients. Am Heart J 2005; 149: 473.
20. Rikitake Y, Kawashima S, Takeshita S et al. Anti-oxidative properties of fluvastatin, an HMG-CoA reductase inhibitor, contribute to prevention of atherosclerosis in cholesterol-fed rabbits. Atherosclerosis 2001; 154: 87–96.
21. Shige H, Dart A, Nestel P. Simvastatin improves arterial compliance in the lower limb but not in the aorta. Atherosclerosis 2001; 155: 245–50.
22. Ferrier KE, Muhlmann MH, Baguet JP et al. Intensive cholesterol reduction lowers blood pressure and large artery stiffness in isolated systolic hypertension. J Am Coll Cardiol 2002; 39: 1020–5.
23. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002; 288: 2981–97.
2. Артериальная гипертония, нарушения липидного обмена и атеросклероз. В.В.Кухарчук. В кн.: Руководство по артериальной гипертонии. Под ред. Е.И.Чазова, И.Е.Чазовой. М.: Медиа Медика, 2005; 289–99.
3. Klahr S, Morrissey JJ. The role of vasoactive compounds, growth factors and cytokines in the progression of renal disease. Kidney Int 2000; 57 (Suppl. 75): 7–14.
4. Wolf G. The Renin-Angiotensin System and Progression of Renal Disease. Jn: Contributions to Nephrology. Editor G. Wolf. 2001.
5. Delcayre C, Swynghedauw B. Molecular mechanisms of myocardial remodelling. The role of aldosterone. J Mol Cell Cardiology 2002; 34: 1577–84.
6. Ross R. Atherosclerosis an inflammatory disease. N Engl J Med 1999; 340:115–26.
7. O’Donnell VB. Free radicals and lipid signaling in endothelial cells. Antiox Redox Signal 2003; 5: 195–203.
8. Wolfrum S, Jensen KS, Liao JK. Endothelium-dependent effects of statins. Arterioscler Thromb Vasc Biol. 2003; 23: 729–36.
9. Kaplan M, Aviram M. Oxidized low density lipoprotein: atherogenic and proinflammatory characteristics during macrophage foam cell formation. An inhibitory role for nutritional antioxidants and serum paraoxonase. ClinChem Lab Med 1999; 37: 777–87.
10. Campese VM, Bianchi S, Bigazzi R. Association between hyperlipidemia andmicroalbuminuria in essential hypertension. Kidney Int 1999; 56 (Suppl. 71): S10–3.
11. Stary HC, Blankenhorn DH, Chandler AB et al. A definition of the intima of human arteries and of its atherosclerosis-prone regions: a report from the Committee on Vascular Lesions of the Council on Arteriosclerosis, American Heart Association. Special report. Circulation 1992; 85: 391–405. [Medline]
12. Dartsch PC, Bauriedel G, Schinko I et al. Cell constitution and characteristics of human atherosclerotic plaques selectively removed by percutaneous atherectomy. Atherosclerosis 1989; 80: 149–57.
13. Blacker DJ, Flemming KD, Link MJ, Brown RD Jr. The preoperative cerebrovascular consultation: common cerebrovascular questions before general or cardiac surgery. Mayo Clin Proc 2004; 79: 223–9.
14. Kalinowski L, Dobrucki LW, Brovkovych V, Malinski T. Increased nitric oxide bioavailability in endothelial cells contributes to the pleiotropic effect of cerivastatin. Circulation 2002; 105: 933–8
15. Kalinowski L, Dobrucki LW, Malinski T. Cerivastatin potentiates nitric oxide release and eNOS expression through inhibition of isoprenoids synthesis. J Physiol Pharmacol 2002; 53: 585–95.
16. Morikawa S, Takabe W, Mataki C et al. The effect of statins on mRNA levels of genes related to inflammation, coagulation and vascular constriction in HUVEC. Human umbilical vein endothelial cells. J Atheroscler Thromb 2002; 9: 177–83.
17. Laufs U, Gertz K, Dirnagl U et al. Rosuvastatin, a new-CoA reductase inhibitor, upregulates endothelial nitric oxide synthase and protects from ischaemic stroke in mice. Brain Res 2002; 942: 23–30.
18. Dahlof B, Poulter N, Sever PS. Do statins lower blood pressure? Evidence from the Anglo-Scandinavian Cardiac Outcomes Trial – Lipid-Lowering Arm (ASCOT-LLA) (abstract). Circulation 2004; 110: 402.
19. John S, Schneider MP, Delles C et al. Lipid-independent effects of statins on endothelial function and bioavailability of nitric oxide in hypercholesterolemic patients. Am Heart J 2005; 149: 473.
20. Rikitake Y, Kawashima S, Takeshita S et al. Anti-oxidative properties of fluvastatin, an HMG-CoA reductase inhibitor, contribute to prevention of atherosclerosis in cholesterol-fed rabbits. Atherosclerosis 2001; 154: 87–96.
21. Shige H, Dart A, Nestel P. Simvastatin improves arterial compliance in the lower limb but not in the aorta. Atherosclerosis 2001; 155: 245–50.
22. Ferrier KE, Muhlmann MH, Baguet JP et al. Intensive cholesterol reduction lowers blood pressure and large artery stiffness in isolated systolic hypertension. J Am Coll Cardiol 2002; 39: 1020–5.
23. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002; 288: 2981–97.
Авторы
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.